title: [Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks(review)].
abstract: Recently published results of II and II phase clinical trials of alemtuzumab in relapsing-remitting multiple sclerosis (MS) are reviewed. This drug has an immunosuppressive mechanism of action with an anti-inflammatory effect higher than that of high-dose beta-interferon. Its neuroprotective activity and possible side-effects are discussed.
authors.forename: M A
authors.initials: MA
authors.lastname: Khasaeva
authors.forename: T V
authors.initials: TV
authors.lastname: Gorokhova
authors.forename: A N
authors.initials: AN
authors.lastname: Boĭko
authors.forename: E I
authors.initials: EI
authors.lastname: Gusev
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074323:Alemtuzumab